معرفی
Oyunbileg Magvanjav, MD, PhD is a Clinical Fellow in the Yale School of Medicine's Department of Internal Medicine, specializing in Endocrinology and Metabolism. They hold a dual MD-PhD from the University of Florida College of Medicine and College of Pharmacy, followed by residency training at Vanderbilt University Medical Center. Currently in the Physician-Scientist Training Program, their research focuses on endocrine disorders, drug efficacy, and pharmacogenomics. Magvanjav has contributed to studies on hypertension management, genetic influences on blood pressure, and clinical outcomes of genotype-guided therapies. They have published extensively in journals like Am J Hypertens, Stroke, and Circ Genom Precis Med. Their work integrates clinical practice with translational research, particularly in optimizing antihypertensive therapies and understanding genetic factors in cardiovascular health.
Education highlights include:
- MD-PhD, University of Florida (2020)
- Residency, Vanderbilt University (2022)
- Fellowship, Yale School of Medicine (current)
Research interests span endocrine/metabolic disorders, pharmacogenetic applications, and clinical trial outcomes. Notably, their work addresses disparities in blood pressure control among chronic kidney disease patients and evaluates genetic markers for therapy personalization. Magvanjav's studies often involve multi-site collaborations, such as the PEAR and INVEST trials.
